结直肠癌抗血管生成疗法反应的动态生物标志物：综述。

Q4 Pharmacology, Toxicology and Pharmaceutics

Current Pharmacogenomics and Personalized Medicine Pub Date : 2017-12-01 DOI:10.2174/1875692115666170815161754

Jesus Rodriguez-Pascual, Antonio Cubillo

{"title":"结直肠癌抗血管生成疗法反应的动态生物标志物：综述。","authors":"Jesus Rodriguez-Pascual, Antonio Cubillo","doi":"10.2174/1875692115666170815161754","DOIUrl":null,"url":null,"abstract":"Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several stu-dies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal anti-body.Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":"15 2","pages":"81-85"},"PeriodicalIF":0.0000,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/c1/CPPM-15-81.PMC5872368.pdf","citationCount":"0","resultStr":"{\"title\":\"Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review.\",\"authors\":\"Jesus Rodriguez-Pascual, Antonio Cubillo\",\"doi\":\"10.2174/1875692115666170815161754\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several stu-dies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal anti-body.Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.\",\"PeriodicalId\":11056,\"journal\":{\"name\":\"Current Pharmacogenomics and Personalized Medicine\",\"volume\":\"15 2\",\"pages\":\"81-85\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/c1/CPPM-15-81.PMC5872368.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Pharmacogenomics and Personalized Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1875692115666170815161754\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacogenomics and Personalized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875692115666170815161754","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

摘要

背景：鉴定临床和分子生物标志物以预测动态反应或实时监测抗血管生成治疗的疗效，是晚期结直肠癌患者治疗中的一个重点。目前已经开展了多项研究，以确定一些预测性生物标志物，从而选择从贝伐单抗（最广泛使用的抗血管生成单克隆抗体）中获益的患者：结论：贝伐珠单抗问世十年后，常规临床实践中仍没有有效的预测性生物标志物。在这篇综述中，我们总结了可能在这种情况下发挥作用的潜在候选动态生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review.

Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several stu-dies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal anti-body.

Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Pharmacogenomics and Personalized Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

0.40

自引率

0.00%

发文量

期刊介绍： Current Pharmacogenomics and Personalized Medicine (Formerly ‘Current Pharmacogenomics’) Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services.